Annotation Detail
Information
- Associated Genes
- NF1
- Associated Variants
-
NF1 MUTATION
NF1 MUTATION - Associated Disease
- skin melanoma
- Source Database
- CIViC Evidence
- Description
- Preclinical study of mouse melanoma both in-vitro and in-vivo. Braf/Nf1-mutant melanomas were less sensitive to vemurafenib than the MEK inhibitor PD0325901. mTOR inhibition with rapamycin had a more pronounced effect than GDC-0941 on mouse melanoma, but synergized with PD0325901(but not vemurafenib) to promote tumor regression.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1469
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3867
- Variant URL
- https://civic.genome.wustl.edu/links/variants/587
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Skin Melanoma
- Evidence Direction
- Supports
- Drug
- Sirolimus,MEK Inhibitor PD0325901
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23171796
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| MEK Inhibitor PD0325901 | Sensitivity | true |
| Sirolimus | Sensitivity | true |